Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital

Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Declining incidence of dementia: A national registry-based study over 20 years

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Liu Shi
  • Sarah Westwood
  • Alison L Baird
  • Laura Winchester
  • Valerija Dobricic
  • Fabian Kilpert
  • Shengjun Hong
  • Andre Franke
  • Abdul Hye
  • Nicholas J Ashton
  • Angharad R Morgan
  • Isabelle Bos
  • Stephanie J B Vos
  • Noel J Buckley
  • Mara Ten Kate
  • Philip Scheltens
  • Rik Vandenberghe
  • Silvy Gabel
  • Karen Meersmans
  • Sebastiaan Engelborghs
  • Ellen E De Roeck
  • Kristel Sleegers
  • Giovanni B Frisoni
  • Olivier Blin
  • Jill C Richardson
  • Régis Bordet
  • José L Molinuevo
  • Lorena Rami
  • Anders Wallin
  • Petronella Kettunen
  • Magda Tsolaki
  • Frans Verhey
  • Alberto Lleó
  • Daniel Alcolea
  • Julius Popp
  • Gwendoline Peyratout
  • Pablo Martinez-Lage
  • Mikel Tainta
  • Peter Johannsen
  • Charlotte E Teunissen
  • Yvonne Freund-Levi
  • Lutz Frölich
  • Cristina Legido-Quigley
  • Frederik Barkhof
  • Kaj Blennow
  • Henrik Zetterberg
  • Susan Baker
  • B Paul Morgan
  • Johannes Streffer
  • Pieter Jelle Visser
  • Lars Bertram
  • Simon Lovestone
  • Alejo J Nevado-Holgado
View graph of relations

INTRODUCTION: Plasma proteins have been widely studied as candidate biomarkers to predict brain amyloid deposition to increase recruitment efficiency in secondary prevention clinical trials for Alzheimer's disease. Most such biomarker studies are targeted to specific proteins or are biased toward high abundant proteins.

METHODS: 4001 plasma proteins were measured in two groups of participants (discovery group = 516, replication group = 365) selected from the European Medical Information Framework for Alzheimer's disease Multimodal Biomarker Discovery study, all of whom had measures of amyloid.

RESULTS: A panel of proteins (n = 44), along with age and apolipoprotein E (APOE) ε4, predicted brain amyloid deposition with good performance in both the discovery group (area under the curve = 0.78) and the replication group (area under the curve = 0.68). Furthermore, a causal relationship between amyloid and tau was confirmed by Mendelian randomization.

DISCUSSION: The results suggest that high-dimensional plasma protein testing could be a useful and reproducible approach for measuring brain amyloid deposition.

Original languageEnglish
JournalAlzheimer's & dementia : the journal of the Alzheimer's Association
Issue number11
Pages (from-to)1478-1488
Number of pages11
Publication statusPublished - Nov 2019

    Research areas

  • Amyloid β, Causal relationship, Plasma proteomics, Replication, SOMAscan assay, Tau

ID: 57975462